Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION (CDM RX-186936) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 30, 2026 , from http://ppman.hank.ai/transparency/procedure/RX-186936/by-state?code_type=CDM
“NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION (CDM RX-186936) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/RX-186936/by-state?code_type=CDM. Accessed
October 30, 2026 .
“NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION (CDM RX-186936) by State,” HANK Price Transparency ,
accessed October 30, 2026 ,
http://ppman.hank.ai/transparency/procedure/RX-186936/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
RX-186936 — Nivolumab 240 Mg-relatlimab-rmbw 80 Mg/20 Ml Intravenous Solution
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$52,263
National median
$31,624 – $59,730
IQR (p25 – p75)
4
hospitals filing
1
states
Walking in without insurance?
Cash / self-pay price
Cash median
$39,758
vs. negotiated
-23.9%
Hospitals reporting
4
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for RX-186936 (CDM), with interquartile range
State Median p25 p75
AL $52,263 $31,624 $59,730